65,437 trials
Pain
Primary: Patients With Clinical Signs of Respiratory Depression or Sub Clinical Respiratory Depressions Measured by Capnography and Pulse Oximetry. — 22; 21 Participants
Urinary Tract Infections · Pyelonephritis
Primary: Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy — 95.5; 98.6; 98.7 Percentage of Participants — p=0.005
Chemotherapeutic Agent Toxicity · Colorectal Cancer · Neuropathy
Primary: Sensory Area Under the Curve(AUC) Score. Oxaliplatin-induced Sensory Neuropathy as Repeatedly Measured by the EORTC QLQ-CIPN20 Sensory Subscale During Chemotherapy…
Bronchopulmonary Dysplasia · Very Low Birth Weight
Primary: Change in Respiratory Resistance — 0.011; 0.006; 0.014 cm h2o/mL/sec
Hypertension, Pregnancy-Induced · Pre-eclampsia
Primary: Difference in Systolic Blood Pressure (SBP) — 131.8; 132.0; 129.1; 129.1 mmHg
Pantothenate Kinase-Associated Neurodegeneration
Primary: Change in Score on Barry-Albright Dystonia Scale — 2.48; 3.99 score on a scale — p=0.0761
Ocular Hypertension · Glaucoma
Primary: Intraocular Pressure in mmHg — 19.01; 19.84; 18.95 Intraocular Pressure in mmHg
Childhood Traumatic Grief · Post Traumatic Stress · Post Traumatic Stress Disorder
Primary: Posttraumatic Stress Syndrome (PTSS) — 23.41; 21.23; 25.66; 23.40 score on a scale
Basal Cell Carcinoma
Primary: Efficacy of Vismodegib — 2; 5; 1; 1 tumors
HIV Infections
Primary: Proportion of Participants With Grade 3 or Higher Adverse Events (AEs) in Cohorts 1-3 Romidepsin Arms — 0 proportion of participants
Hidradenitis Suppurativa (Acne Inversa)
Primary: Clinical Responder Rate at Period 1: Week 16 — 10; 4 participants
Insulin Resistance · Postmenopause
Primary: Percent Change in Free Testosterone (T) — -6.9; -35.8; 12.1 percent change
Acute Respiratory Failure
Primary: Treatment Failure Rate — 13; 7; 87; 97 Participants
Acute Coronary Syndrome
Primary: 7-Day Point Prevalence Smoking Abstinence — 70; 49 Participants
Colorectal Neoplasms
Primary: Proportion of Participants With Grade 2-4 Toxicities — 0.63; 0.40 proportion of participants